A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO studyÖ. Türeci, Martin Schüler, Ahsan M. Arozullah et al.|Annals of Oncology|2019Cited by 244
Modest improvement in overall survival for patients with metastatic pancreatic cancer: a trend analysis using the surveillance, epidemiology, and end results registry from 1988 to 2008.Mathias Worni, Dieter Koeberle, Ulrich Güller et al.|PubMed|2013Cited by 74
Modest Improvement in Overall Survival for Patients With Metastatic Pancreatic CancerMathias Worni, Dieter Koeberle, Ulrich Güller et al.|Pancreas|2013Cited by 66
Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort studyMarkus Joerger, Thomas Cerny, C. Schaer-Thuer et al.|European Journal of Clinical Pharmacology|2014Cited by 28